SEC Form 4
| FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
| 2. Issuer Name and Ticker or Trading Symbol SYNAPTICS Inc [ SYNA ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| ||||||||||||||||||||||||
| 3. Date of Earliest Transaction (Month/Day/Year) 02/08/2021 | ||||||||||||||||||||||||||
| 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||||||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 02/08/2021 | M | 3,000 | A | $79.38 | 17,860 | D | |||
| Common Stock | 02/08/2021 | M | 2,725 | A | $89.29 | 20,585 | D | |||
| Common Stock | 02/08/2021 | M | 3,000 | A | $76.81 | 23,585 | D | |||
| Common Stock | 02/08/2021 | M | 3,000 | A | $85.69 | 26,585 | D | |||
| Common Stock | 02/08/2021 | M | 2,725 | A | $73.31 | 29,310 | D | |||
| Common Stock | 02/08/2021 | M | 2,725 | A | $71.55 | 32,035 | D | |||
| Common Stock | 02/08/2021 | S | 3,100 | D | $117.4691(1) | 28,935 | D | |||
| Common Stock | 02/08/2021 | S | 8,190 | D | $118.6601(2) | 20,745 | D | |||
| Common Stock | 02/08/2021 | S | 1,674 | D | $120.4336(3) | 19,071 | D | |||
| Common Stock | 02/08/2021 | S | 4,211 | D | $121.4666(4) | 14,860 | D | |||
| Common Stock | 02/09/2021 | M | 2,725 | A | $51.95 | 17,585 | D | |||
| Common Stock | 02/09/2021 | M | 3,575 | A | $52.57 | 21,160 | D | |||
| Common Stock | 02/09/2021 | M | 3,575 | A | $54.36 | 24,735 | D | |||
| Common Stock | 02/09/2021 | M | 3,575 | A | $54.77 | 28,310 | D | |||
| Common Stock | 02/09/2021 | S | 1,400 | D | $121.4081(5) | 26,910 | D | |||
| Common Stock | 02/09/2021 | S | 4,328 | D | $122.591(6) | 22,582 | D | |||
| Common Stock | 02/09/2021 | S | 7,722 | D | $123.0166(7) | 14,860 | D | |||
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Employee Stock Option (Right to Buy) | $79.38 | 02/08/2021 | M | 3,000 | (8) | 07/31/2022 | Common Stock | 3,000 | $0.00 | 0 | D | ||||
| Employee Stock Option (Right to Buy) | $89.29 | 02/08/2021 | M | 2,725 | (9) | 10/23/2022 | Common Stock | 2,725 | $0.00 | 0 | D | ||||
| Employee Stock Option (Right to Buy) | $76.81 | 02/08/2021 | M | 3,000 | (10) | 01/30/2022 | Common Stock | 3,000 | $0.00 | 0 | D | ||||
| Employee Stock Option (Right to Buy) | $85.69 | 02/08/2021 | M | 3,000 | (11) | 04/24/2022 | Common Stock | 3,000 | $0.00 | 0 | D | ||||
| Employee Stock Option (Right to Buy) | $73.31 | 02/08/2021 | M | 2,725 | (12) | 01/29/2023 | Common Stock | 2,725 | $0.00 | 0 | D | ||||
| Employee Stock Option (Right to Buy) | $71.55 | 02/08/2021 | M | 2,725 | (13) | 04/29/2023 | Common Stock | 2,725 | $0.00 | 0 | D | ||||
| Employee Stock Option (Right to Buy) | $51.95 | 02/09/2021 | M | 2,725 | (14) | 07/29/2023 | Common Stock | 2,725 | $0.00 | 0 | D | ||||
| Employee Stock Option (Right to Buy) | $52.57 | 02/09/2021 | M | 3,575 | (15) | 10/28/2023 | Common Stock | 3,575 | $0.00 | 0 | D | ||||
| Employee Stock Option (Right to Buy) | $54.36 | 02/09/2021 | M | 3,575 | (16) | 01/27/2024 | Common Stock | 3,575 | $0.00 | 0 | D | ||||
| Employee Stock Option (Right to Buy) | $54.77 | 02/09/2021 | M | 3,575 | (17) | 04/28/2024 | Common Stock | 3,575 | $0.00 | 0 | D | ||||
| Explanation of Responses: |
| 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.92 to $117.79, inclusive. The reporting person undertakes to provide to Synaptics Incorporated (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118 to $118.94, inclusive. The reporting person undertakes to provide to Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.92 to $120.79, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.928 to $121.740, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.95 to $121.91, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122 to $122.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123 to $123.14, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 8. 1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the July 31, 2015 date of grant, until fully vested on July 31, 2018. |
| 9. 1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the October 23, 2015 date of grant, until fully vested on October 23, 2018. |
| 10. 1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the January 30, 2015 date of grant, until fully vested on January 30, 2018. |
| 11. 1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the April 24, 2015 date of grant, until fully vested on April 24, 2018. |
| 12. 1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the January 29, 2016 date of grant, until fully vested on January 29, 2019. |
| 13. 1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the April 29, 2016 date of grant, until fully vested on April 29, 2019. |
| 14. 1/12th of the total number of shares subject to the option vested and became exercisable each quarter following the July 29, 2016 date of grant, until fully vested on July 29, 2019. |
| 15. 33% of the total number of shares subject to the option vested and became exercisable one year following the vesting commencement date of October 28, 2016, with the remaining 2/3rds vesting quarterly until fully vested on October 28, 2019. |
| 16. 33% of the total number of shares subject to the option vested and became exercisable one year following the vesting commencement date of January 27, 2017,with the remaining 2/3rds vesting quarterly until fully vested on January 27, 2020. |
| 17. 33% of the total number of shares subject to the option vested and became exercisable one year following the vesting commencement date of April 28, 2017, with the remaining 2/3rds vesting quarterly until fully vested on April 28, 2020. |
| Remarks: |
| The reporting person is SVP, General Counsel & Secretary. |
| /s/ Kermit Nolan, as attorney-in-fact | 02/10/2021 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||